Log in

Relevant bibliographies by topics / Antimycobacterial effect of alternative treatments used in Alzheimer's

Contents

Journal articles

Academic literature on the topic 'Antimycobacterial effect of alternative treatments used in Alzheimer's'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antimycobacterial effect of alternative treatments used in Alzheimer's.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antimycobacterial effect of alternative treatments used in Alzheimer's"

1

Dr., Lawrence Broxmeyer MD. "Alzheimer's FDA Approved Drugs & Alternatives: What are They Really Treating?" Current Opinions in Neurological Science 3, no. 1 (2018): 613–23. https://doi.org/10.5281/zenodo.2247890.

Full text

Abstract:

A 2018 study by Tricco <em>et al</em>, ranking the safety and effectiveness of the four leading drugs now taken to enhance concentration, memory, alertness and moods in, found that donepezil (Aricept®) was most likely to effectively improve cognition in patients with Alzheimer's dementia. However, patients who took donepezil were more likely to experience side effects including nausea, vomiting and diarrhea than those who received a placebo, according to the study, published online in the <em>Journal of the American Geriatrics Society</em>.<sup>1</sup> And an earlier study showed that

APA, Harvard, Vancouver, ISO, and other styles

2

Ferreira Schopf, Patricia, Mikaela Peglow Pinz, Ketlyn Pereira da Motta, et al. "SAFETY PROFILE AND PREVENTION OF COGNITIVE DEFICIT IN ALZHEIMER’S DISEASE MODEL OF GRAPHENE FAMILY NANOMATERIALS, TUCUMA OIL (Astrocaryum vulgare) AND ITS SYNERGISMS." International Journal for Innovation Education and Research 10, no. 3 (2022): 267–303. http://dx.doi.org/10.31686/ijier.vol10.iss3.3694.

Full text

Abstract:

Alzheimer's disease is a worldwide health issue, and there are currently no treatments that can stop this disease. Oxidized graphene derivatives have gained prominence in use in biological systems due to their excellent physical-chemical characteristics, biocompatibility and ability to overcome the blood-brain barrier. Other substances highlighted are those of natural origin from the Amazon biome, such as tucuma, a fruit whose oil has been widely studied in therapeutic applications. Thus, the aim of this study was to investigate the action of graphene oxide, reduced graphene oxide and tucuma o

APA, Harvard, Vancouver, ISO, and other styles

3

Ni Kadek Yuni Lestari, Yuni, Ni Luh Putu Thrisna Dewi, and Ni Made Era Mahayani. "The Effect of Feet Reflection Massage on Blood Pressure in Hypertension Patients at Community Health Centers II Petang." Nursing and Health Sciences Journal (NHSJ) 3, no. 1 (2023): 56–60. http://dx.doi.org/10.53713/nhs.v3i1.151.

Full text

Abstract:

Complications of hypertension cause various health problems such as kidney damage, heart attack, stroke, glaucoma, erectile dysfunction, dementia and alzheimer's. One of the non-pharmacological treatments to avoid the long-term effects of hypertension is foot reflexology therapy. Foot reflexology therapy is a therapy that suppresses the zones and nerve points on the right and left soles of the feet. This study aims to determine the effect of foot reflexology on blood pressure in patients with hypertension. This type of research is a Quasi Experiment with a Non-Equivalent Control Group Design.

APA, Harvard, Vancouver, ISO, and other styles

4

Djeuzong, Etienne, Antoine K. Kandeda, Séfirin Djiogue, et al. "Antiamnesic and Neuroprotective Effects of an Aqueous Extract of Ziziphus jujuba Mill. (Rhamnaceae) on Scopolamine-Induced Cognitive Impairments in Rats." Evidence-Based Complementary and Alternative Medicine 2021 (August 10, 2021): 1–15. http://dx.doi.org/10.1155/2021/5577163.

Full text

Abstract:

Background. Alzheimer's disease is a neurological condition that affects about 44 million people worldwide. The available treatments target symptoms rather than the underlying causes. Ziziphus jujuba (Rhamnaceae) is widely used in traditional Cameroonian medicine to treat diabetes, pain, infections, and dementia. Previous studies reported that Z. jujuba aqueous macerate improves working memory impairment, but no study on the antiamnesic effect of a concoction of Z. jujuba in rats has been performed. Therefore, this study aimed to assess the antiamnesic and neuroprotective effects of an aqueous

APA, Harvard, Vancouver, ISO, and other styles

5

Ali-Shtayeh, Mohammed Saleem, Rana Majed Jamous, Salam Yousef Abu Zaitoun, and Iman Basem Qasem. "In-vitro screening of acetylcholinesterase inhibitory activity of extracts from Palestinian indigenous flora in relation to the treatment of Alzheimer’s disease." Functional Foods in Health and Disease 4, no. 9 (2014): 381. http://dx.doi.org/10.31989/ffhd.v4i9.149.

Full text

Abstract:

Background: Cholinesterase inhibitory therapy serves as a strategy for the treatment of Alzheimer’s disease (AD). Several acetylcholinesterase inhibitors (AChEIs) are used for the symptomatic treatment of AD. These compounds have been reported to have adverse effects, including gastrointestinal disturbances. This study was therefore partly aimed at investigating in vitro possible AChEIs in herbal medicines traditionally used in Palestine to treat cognitive disorders, and to point out the role of these plants as potential sources for development of newly potent and safe natural therapeutic agen

APA, Harvard, Vancouver, ISO, and other styles

6

Dearsly, Emmanuel Markus, Kingsley Chijioke Eze, Constance Adaeze Chukwu, and Lilian William Ofem. "Insilico Studies and Pharmacokinetic Properties of Anti-Alzheirmer's Disease Activities of Phytocompounds Derived from Lasianthera Africana." International Journal of Novel Research in Life Sciences 11, no. 5 (2024): 58–73. https://doi.org/10.5281/zenodo.13986628.

Full text

Abstract:

<strong>Abstract:</strong> Alzheimer’s disease (AD) is a devastating mental illness with an irreversible progressive brain disorder that slowly destroys memory skills and learning abilities. No treatments stop or reverse the progression of Alzheimer's disease, though some may temporarily improve symptoms. Hence, the limitations of these treatment methods necessitate the search for an alternative among the herbs available to man. Lasianthera africana locally known as "Editan" in Ibibio and Annang tribes of Southern Nigeria, has pharmacological benefits which includes; possession of analge

APA, Harvard, Vancouver, ISO, and other styles

7

Wu, Chao‐Yi, Liu Chen, John R. Dickson, Bo Zhang, Steven E. Arnold, and Hiroko H. Dodge. "Synthetic control methods for n‐of‐1 and parallel‐group trials in Alzheimer's disease: A proof‐of‐concept study using the I‐CONECT." Alzheimer's & Dementia 21, no. 7 (2025). https://doi.org/10.1002/alz.70460.

Full text

Abstract:

AbstractINTRODUCTIONWith the advent of Alzheimer's disease (AD)‐modifying and symptomatic treatments of demonstrated efficacy, enrolling participants as concurrent placebo controls in trials can become increasingly difficult. Synthetic controls have been proposed as a viable alternative to concurrent control groups, but their feasibility and reliability remain untested in AD studies.METHODSI‐CONECT trial, which evaluates conversational interactions on cognition, was used to test synthetic control methods. Data from the National Alzheimer's Coordinating Center‐Uniform Data Set was used to creat

APA, Harvard, Vancouver, ISO, and other styles

8

Cummings, Jeffrey. "Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials." Alzheimer's & Dementia: Translational Research & Clinical Interventions 11, no. 1 (2025). https://doi.org/10.1002/trc2.70059.

Full text

Abstract:

AbstractThe minimum clinically important difference (MCID) is a measure of the minimal clinically relevant change. The MCID represents the smallest difference in score on the measure or domain of interest which patients or clinicians perceive as beneficial or as meaningful decline. The MCID is not an alternative clinical trial outcome; it does not apply to group measures and is used as a means of determining whether an individual patient has reached a threshold of change. MCIDs have been derived for symptomatic treatments and for disease targeted therapies. MCIDs have been derived for nearly a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!